Rationale: Mesenchymal stem cells (MSCs) improve function after infarction, but their mechanism of action remains unclear, and the importance of reduced scar volume, cardiomyocyte proliferation, and perfusion is uncertain.
M esenchymal stem cells (MSCs) can repair a variety of tissues after injury 1 and are currently being used in clinical trials to treat patients with cardiovascular disease. 2 Nevertheless, their precise mechanism of action and the role of myocyte regeneration versus angiogenesis are controversial. Most preclinical investigation has focused on animal models of myocardial infarction in which intravenous, intramyocardial, and intracoronary administration of MSCs have been demonstrated to reduce infarct size and improve left ventricular (LV) function in both acute and chronic infarction. [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] Although early studies demonstrated the ability of autologous and allogeneic MSCs to differentiate into vessels, 8, 14 smooth muscle, 14 and cardiac muscle, 15, 16 the quantitative extent of MSC differentiation into a cardiac cellular phenotype has been small and inconsistent with measured reductions in infarct volume. 4, 8, 11 Recent investigations have hypothesized that MSCs effect cardiac repair through a paracrine mechanism that stimulates proliferation of endogenous myocytes, but in vivo studies quantifying the magnitude of myocyte proliferation are limited. Most analyses focus on the small rim of border zone tissue between normal and infarcted myocardium rather than larger remote regions or areas at risk of ischemia. 5, 9, [17] [18] [19] [20] [21] [22] increase in myocardial perfusion. Although BMPC mobilization had no effect on myocyte proliferation in the normal heart, it increased the frequency of myocytes in the proliferative phase of the cell cycle in diseased hearts and increased myocyte nuclear density with small myocytes that suggested that endogenous myocyte proliferation was stimulated. 23 Likewise, studies with skeletal muscle injection of porcine MSCs into Syrian hamsters 24 and MSCs that overexpressed insulin-like growth factor-1 9 and Akt 20 in infarcted animals support the notion that paracrine factors can mobilize BMPCs and potentially facilitate cardiac repair.
On the basis of these observations, the known secretion of a variety of growth factors from MSCs, 24, 25 and the demonstrated ability of selected growth factors to mobilize BMPCs, 26 we tested the hypothesis that MSCs stimulate myocyte proliferation through a similar mechanism. To more definitively ascertain the effects of MSCs on angiogenesis and myocyte regeneration independent of infarct volume, we used an in vivo model of hibernating myocardium. In this setting, chronic dysfunction arises from repetitive ischemia in collateral-dependent myocardium, and regional myocyte loss with compensatory cellular hypertrophy develops in the absence of infarction. 27 Thus, changes in regional perfusion and increases in regional myocyte number 23 can be used to assess the regenerative effects of cell-based therapy and exclude preservation of myocytes that arise from inhibition of cell death. We used autologous MSCs expanded ex vivo to circumvent tissue incompatibility with xenogenic or unmatched allogenic cells. Our results in a model devoid of infarction indicate that intracoronary administration of MSCs (icMSCs) can improve function in hibernating myocardium independent of increased perfusion. icMSCs stimulate myocytes to reenter the cell cycle in the diseased but not the normal heart and effect substantial myocyte proliferation and mobilization of endogenous BMPCs.
Methods
Procedures and protocols conformed to institutional guidelines for the care and use of animals in research. Detailed experimental and histological protocols (available in the Online Data Supplement at http://circres.ahajournals.org) have been described previously. 23
Effects of icMSCs on Flow and Function in Hibernating Myocardium (n‫)71؍‬
Pigs were chronically instrumented with a 1.5-mm Delrin stenosis on the proximal left anterior descending coronary artery (LAD) as described previously (online Data Supplement). 28 We performed 2 baseline physiological studies 3 and 4 months after instrumentation to establish that stable reductions in LAD wall thickening and resting LAD perfusion were present before icMSC injection (Online Figure I) . Under propofol sedation, a Millar catheter was inserted into the LV for microsphere injection. Regional wall thickening was assessed with echocardiography. Microsphere flow was assessed at rest and after adenosine vasodilation. At the 4-month study, animals received icMSCs (44ϫ10 6 , nϭ10) and were studied 2 weeks (nϭ6) or 6 weeks (nϭ4) later. In 4 animals, MSCs were transfected with adenovirus encoding enhanced green fluorescent protein to determine myocardial differentiation. After physiological measurements, the heart was excised for flow and histological analyses. Results were compared with untreated animals with hibernating myocardium (nϭ7).
Mobilization of BMPCs With icMSCs (n‫)6؍‬
We assessed the ability of icMSCs to mobilize BMPCs (cKit ϩ and CD133 ϩ mononuclear cells) in normal swine as detailed in the online Data Supplement. Baseline measurements in peripheral blood (30 mL) were compared with those 3 days and 2 weeks after administration of icMSCs. Data from fluorescent activated cell sorter analysis are expressed as CD133 ϩ or cKit ϩ cells per 1 million mononuclear cells.
Myocardial Histopathology
Histopathology in animals that received MSCs was compared with untreated animals. We assessed the temporal evolution of myocardial proliferation by evaluating animals studied at 2 and 6 weeks after icMSC administration compared with untreated animals with hibernating myocardium. We also compared the effects of icMSCs in shamnormal animals (nϭ6) to that in untreated sham-normal animals (nϭ5).
To determine whether increases in BMPCs were caused by microembolization, we evaluated myocardial progenitor cell levels in normal swine (nϭ6) in which MSCs were infused into the distal aorta. The histopathologic and immunohistochemical techniques have been presented previously 23 and are discussed in the online Data Supplement.
Myocyte Nuclear Density and Morphometry
Samples from hibernating LAD and normal remote regions were fixed and paraffin embedded. Trichrome-stained sections were used to quantify connective tissue. 27 Periodic acid-Schiff-stained sections were used to quantify myocyte diameter, nuclear length, and regional myocyte nuclear density.
Quantitative Analysis of Myocyte Proliferation and Myocardial cKit ؉ and CD133 ؉ Cells
To identify myocyte proliferation, anti-Ki67 and anti-phosphohistone H3 staining were performed. 29 BMPCs (cKit ϩ /CD133 ϩ ) and presumed resident cardiac stem cells (cKit ϩ /CD133 Ϫ ) were quantified by confocal immunofluorescence (online Data Supplement). Preliminary studies demonstrated that tissue CD133 ϩ and cKit ϩ cells were CD45 Ϫ . These were costained with GATA-4, Nkx2.5, and cardiac troponin I antibodies to determine the extent to which each population differentiated into a cardiac lineage. 14
Statistical Analysis
Data are expressed as meanϮSE. Differences between groups were assessed by 2-way ANOVA and the post hoc Holm-Sidak test. Temporal physiological changes between initial and final studies were assessed by paired t tests with each animal used as its own control. For all comparisons, PϽ0.05 was considered significant.
Results
All animals were in good health at the time of study. Baseline studies performed at 4 months confirmed dysfunctional hibernating myocardium (nϭ17). Regional LAD wall thickening (LAD%WT) was reduced compared with normal remote regions (24Ϯ2% versus 64Ϯ4%, PϽ0.05), with reductions in resting perfusion (LAD 0.72Ϯ0.06 versus 0.94Ϯ0.05 mL ⅐ min Ϫ1 ⅐ g Ϫ1 in remote regions, PϽ0.01). Flow during adenosine was severely attenuated (LAD 1.22Ϯ0.22 versus 4.47Ϯ0.25 mL ⅐ min Ϫ1 ⅐ g Ϫ1 in remote regions, PϽ0.001). Although survival in this animal model is limited by sudden
Non-standard Abbreviations and Acronyms BMPC
bone marrow progenitor cell icMSC intracoronary mesenchymal stem cell LAD%WT percent of left anterior descending coronary artery wall thickening MSC mesenchymal stem cell death, 30 it was similar in each group, with 10 of 13 animals that received icMSCs surviving (77% survival rate) versus 7 of 10 untreated swine (70% survival rate). No sham-normal pigs that received MSCs died. TTC staining did not demonstrate infarction. Increases in LAD interstitial connective tissue were similar in pigs that received icMSCs versus those that were untreated (LAD 8.6Ϯ0.9% versus 6.6Ϯ1.4%, PϭNS; remote 5.2Ϯ0.5% versus 4.1Ϯ0.8%, PϭNS). When icMSCs were transfected with adenovirus encoding enhanced green fluorescent protein, EGFP ϩ cardiac cells were too rare to quantify, and staining was restricted to endothelium and smooth muscle (data not shown). We did not identify any EGFP ϩ cardiac myocytes.
Effects of icMSCs on Flow and Function
Serial physiological studies before icMSCs confirmed a stable level of dysfunction and a stable critical impairment in coronary flow reserve (Online Figure II) . Serial changes in LAD%WT and coronary flow reserve (adenosine/rest) are summarized in Figure 1 . There was no change in LAD%WT in untreated animals with hibernating myocardium. In contrast, LAD%WT increased 2 and 6 weeks after icMSC administration (PϽ0.05 versus initial baseline). In contrast to animals with hibernating myocardium, icMSCs did not affect LAD%WT in sham-normal hearts (62Ϯ6% versus 57Ϯ10%). Improvements in LAD function were not associated with changes in myocardial perfusion.
When data from hibernating animals that received icMSCs were pooled (nϭ10), regional LAD%WT increased from 23.8Ϯ3.7% to 43.4Ϯ5.3% (PϽ0.05; Online Table I ). The improvement in function was not related to alterations in hemodynamics (Online Table II ) or global function, because ejection fraction was normal (61.3Ϯ2.3% at baseline versus 62.4Ϯ2.1% after icMSCs, PϭNS). LAD flow reserve remained critically depressed and did not increase after icMSCs (1.21Ϯ0.13 initial versus 1.24Ϯ0.14 final). Flow reserve also remained unchanged in remote myocardium (6.1Ϯ0.7 initial versus 5.4Ϯ0.4 final). Likewise, relative reductions in vasodilated flow (LAD/remote) remained unchanged after icMSC administration (0.20Ϯ0.01 initial versus 0.19Ϯ0.02 final).
Increased BMPCs After MSCs
Circulating mononuclear cells were not altered after icMSC administration (from 4395Ϯ842 cells/L to 3881Ϯ788 cells/L after icMSC administration, PϭNS), but selected BMPC populations were transiently mobilized. Three days after icMSC administration, circulating cKit ϩ and CD133 ϩ cells increased 4-fold and remained significantly elevated at 2 weeks (Online Figure III) . Corresponding increases in tissue cKit ϩ /CD45 Ϫ ( Figure 2 ) and CD133 ϩ /CD45 Ϫ (Figure 3 ) cells occurred in hibernating and sham-normal myocardium. After 6 weeks, CD133 ϩ cells returned to control levels, but cKit ϩ cells remained elevated. Costaining with GATA-4 and Nkx2.5 ( Figure 4 ) demonstrated that a small percentage (Ͻ5%) of myocardial cKit ϩ and CD133 ϩ cells were differentiating into a vascular or cardiac muscle lineage, and these increased after icMSC administration. Although there was no troponin I detected in cKit ϩ cells in untreated hibernating myocardium, costaining after icMSC administration was present in 5.6Ϯ1.9% of the cKit ϩ cells (nϭ6). Colocalization of cKit and von Willebrand factor (nϭ4) that identified endothelial commitment occurred in 33Ϯ2% of the cKit ϩ cells.
An estimate of the number of cKit ϩ cells that were resident cardiac stem cells versus CD133 ϩ BMPCs was obtained by dual staining for both cKit and CD133. When assessed 2 weeks after icMSC administration, 41Ϯ5% of the cells were cKit ϩ /CD133 ϩ , and the remainder were cKit ϩ /CD133 Ϫ . Because cKit ϩ resident cardiac stem cells are negative for the hematopoietic surface antigen CD133, this colocalization supports the notion that nearly half of the cKit ϩ cells initially came from sources other than the resident cardiac stem cell pool. In contrast, after 6 weeks, CD133 ϩ cells returned to baseline. The sustained increase in cKit ϩ cells could reflect resident cardiac stem cells or cKit ϩ BMPCs that remained in the myocardium after mobilization by icMSCs.
We infused MSCs into the distal aorta to determine whether increases in cKit ϩ /CD133 ϩ cells were related to myocardial microembolization (supplemental Figure IV) . Aortic MSC infusion increased myocardial cKit ϩ cells from 8Ϯ3ϫ10 3 to 393Ϯ82ϫ10 3 cells/cm 3 versus 819Ϯ209ϫ10 3 cells/cm 3 after icMSC administration (both PϽ0.05 versus untreated). Likewise, myocardial CD133 ϩ cells increased from 5Ϯ2ϫ10 3 to 366Ϯ109ϫ10 3 cells/cm 3 versus 234Ϯ64ϫ 10 3 cells/cm 3 after icMSC administration (both PϽ0.05 versus untreated). Thus, increases in myocardial cKit ϩ / CD133 ϩ progenitor cells did not require intracoronary injection or microembolization of MSCs in the heart.
Autologous icMSCs Stimulate Cardiomyocytes to Reenter the Cardiac Cell Cycle
Although icMSCs labeled with EGFP did not differentiate into cardiomyocytes, they had a profound effect on stim- Figure 1 . icMSCs increase regional function in hibernating myocardium. LAD wall thickening (WT) was depressed compared with remote myocardium (online Data Supplement), and coronary flow reserve was critically impaired and unable to increase in response to adenosine. There was no spontaneous improvement in flow or function in untreated animals (nϭ7). After icMSC administration, regional LAD wall thickening increased significantly, whereas coronary flow reserve remained critically impaired, which indicates the absence of functional collateral development. Increases in LAD%WT were significant in animals studied 2 weeks (nϭ6) and 6 weeks (nϭ4) after icMSC administration.
ulating endogenous myocyte proliferation in diseased but not sham-normal hearts. Figure 5 summarizes the effects of icMSCs on myocyte nuclear Ki67 staining, a marker of proliferation. A single dose of icMSCs increased Ki67 ϩ myocyte nuclei in LAD and in remote regions of dysfunctional hearts for up to 6 weeks (LAD 2234Ϯ892 versus 410Ϯ82 nuclei/10 6 myocyte nuclei, PϽ0.05). There was also a sustained increase in myocyte phospho-histone H3 staining (LAD 213Ϯ16 versus 9Ϯ5 nuclei/10 6 myocyte nuclei, PϽ0.05; Figure 6 ). In contrast, icMSCs did not increase Ki67 or phospho-histone H3-positive myocytes in sham-normals. Thus, increased cardiomyocyte proliferation after icMSC administration was restricted to the diseased heart. Confocal images of a CD133 ϩ cell cluster are shown on the left, but these were more often seen singly throughout the heart. Autologous icMSCs resulted in a marked increase in myocardial CD133 ϩ cells in tissue harvested 2 weeks after administration. After icMSC administration, CD133 ϩ cells increased in dysfunctional LAD regions and remote regions of hibernating animals, as well as in sham-normals. In hibernating tissue harvested 6 weeks after injection, CD133 ϩ cell levels had returned to pretreatment controls. Thus, increases in myocardial CD133 ϩ cells were transient.
Impact of Proliferative Markers on Angiogenesis, Myocyte Numbers, LV Mass, and Myocyte Diameter
Although coronary flow reserve did not change, icMSCs stimulated angiogenesis by increasing capillary density (from 1172Ϯ71/mm 2 in untreated animals to 1441Ϯ60/mm 2 at 2 weeks and 1383Ϯ45/mm 2 at 6 weeks, both PϽ0.05 versus untreated animals; Figure 7 ). To assess the quantitative impact of myocyte proliferative markers on myocyte regeneration in vivo, we also quantified myocyte nuclear density ( Figure 8 ). As reported previously, 27 LAD myocyte nuclear density was reduced, with compensatory myocyte cellular hypertrophy in hibernating LAD regions of untreated animals. After icMSC administration, there was a progressive increase in myocyte nuclear density that became significantly higher than in untreated animals after 6 weeks (1016Ϯ53 versus 830Ϯ41 myocyte nuclei/mm 2 , PϽ0.05). A similar trend was found in remote regions, although the differences did not reach statistical significance (1219Ϯ131 versus 1027Ϯ55 myocyte nuclei/mm 2 ). The calculated myocyte nuclear number per cubic millimeter was even larger (114 424Ϯ 9564 myocyte nuclei/mm 3 after icMSC administration versus 75 336Ϯ5057 myocyte nuclei/mm 3 in untreated myocardium, PϽ0.01) and was accompanied by an increase in postmortem LV mass-to-body weight ratio after icMSC administration (2.8Ϯ0.1 g/kg after icMSC administration versus 2.5Ϯ0.1 g/kg in untreated animals, PϽ0.05). Importantly, the increase in LV mass was not accompanied by cellular hypertrophy, because myocyte diameter actually decreased after icMSC administration (LAD 16.0Ϯ0.4 m to 14.5Ϯ0.4 m after icMSC administration, PϽ0.05; Figure 8 ). Collectively, the increases in nuclear number and LV mass along with the reduced myocyte cell size are all consonant with increased myocyte proliferation after icMSC administration.
Autologous icMSCs Upregulate Chemokines
To ascertain potential paracrine factors responsible for the effects of icMSCs on myocyte proliferation, we quantified the myocardial expression of stromal cell-derived factor-1, monocyte chemotactic protein-1, and vascular endothelial growth factor 2 weeks after icMSC administration. In hibernating myocardium, icMSCs significantly increased stromal cell-derived factor-1 (2.1Ϯ0.2-fold, PϽ0.05 versus untreated) and monocyte chemotactic protein-1 (2.5Ϯ0.7-fold, PϽ0.05 versus untreated) but not vascular endothelial growth factor (1.1Ϯ0.1-fold, PϭNS). Expression was not altered in sham-normal animals that received icMSCs (Online Figure V) .
Discussion
There are several novel and important new findings from the present study. First, although autologous icMSCs do not (Left, arrows) , some of the myocardial cKitϩ cells (green) coexpressed cardiac transcription factors (GATA-4 and Nkx2.5). Similar findings were seen for CD133 ϩ BMPCs. Both cKit ϩ /GATA4 ϩ cells and cKit ϩ /Nkx2.5 cells were increased significantly at 2 and 6 weeks after icMSC administration. In contrast, CD133 ϩ /GATA4 ϩ cells and CD133 ϩ Nkx2.5 ϩ cells were increased only at 2 weeks after icMSC administration. These data indicate that a subpopulation of both cKit ϩ and CD133 ϩ cells coexpressed myocyte transcription factors, which indicates their potential to differentiate into a myocyte lineage.
measurably differentiate into cardiac myocytes in vivo, they mobilize BMPCs, which leads to increased tissue levels of cKit ϩ /CD133 ϩ and cKit ϩ /CD133 Ϫ cells in normal and diseased myocardium. Second, in dysfunctional hearts with preserved perfusion, icMSCs stimulate cardiomyocytes to reenter the proliferative phase of the cell cycle, as reflected by increased Ki67 ϩ and phospho-histone H3-positive myocytes. This is sustained for at least 6 weeks and results in substantial myocyte regeneration, as documented by significant increases in myocyte nuclear number, a reduction in cellular hypertrophy, and an increase in LV mass. Although capillary neoangiogenesis occurs, there is no improvement in coronary flow reserve. The findings support the central role of myocyte regeneration and regression of cellular hypertrophy in functional improvement, because this model is devoid of heart failure, infarction, and ongoing cell death. There was no effect of icMSCs on phosphohistone H3 in sham-normals (left graph). In contrast, icMSCs increased the number of myocytes in the mitotic phase of the cardiac cycle in hibernating myocardium, and this persisted up to 6 weeks after injection (right graph).
Effect of icMSCs on Flow, Function, Myocyte Number, and LV Mass
Previous studies have fairly consistently demonstrated the ability of a variety MSC formulations (autologous, allogenic, and xenogenic) to improve myocardial function in animal models of infarction. 8,11,14 -16,31 Although intramyocardial MSC injection variably reduces infarct size and improves function, the mechanisms of action have remained unclear. Existing studies have largely restricted histological analysis of myocyte regeneration to the thin rim of border zone tissue, and thus, the magnitude of myocyte regeneration in the heart has not been quantified. Although some studies demonstrate that MSCs can differentiate into myocytes, 15 other studies are consistent with our observations showing that MSC differentiation into a cardiac lineage is a rare phenomenon, 14 with only vascular cells colabeled with MSCs transfected with adenovirus encoding enhanced green fluorescent protein. Although this approach may have underestimated the retention and differentiation of MSCs into a cardiac phenotype, previous experiments using DAPI-labeled MSCs demonstrated that only 2% of icMSCs were retained in the heart after 2 weeks. 32 A similar low retention has been demonstrated for other cell types through intracoronary or direct myocardial injection, including cardiac stem cells, embryonic stem cells, CD133 ϩ cells, and MSCs. [33] [34] [35] [36] [37] Thus, the rare transdifferentiation of MSCs into a cardiac phenotype reported by others 38 cannot explain the substantial increase in cardiomyocytes and regression of cellular hypertrophy in our model.
Many laboratories have found MSCs to increase angiogenesis in infarct border zones, but their effect on maximal perfusion is unknown. Interpretation of capillary density
surrounding an infarct is difficult, because MSC-mediated preservation of existing myocardium would preserve capillary density without vascular regeneration. Because our model of collateral-dependent hibernating myocardium was devoid of infarction and apoptosis when studies began, we were able to examine a large, homogeneously perfused dysfunctional region and dissociate the effects of icMSCs on vascular remodeling and myocyte proliferation from these confounding effects. We found that icMSCs stimulated capillary neoangiogenesis. Interestingly, the relative increase in capillary density in hibernating myocardium was closely matched to the increase in myocardial nuclear density after Figure 7 . icMSCs increased capillary density in hibernating myocardium. Capillary density was quantified with von Willebrand factor (vWF). Upper photomicrographs show vWF staining (green) from hibernating myocardium. Animals that received icMSCs increased capillary density at 2 and 6 weeks vs untreated animals (both PϽ0.05 vs untreated; lower graph). Although icMSCs stimulated capillary angiogenesis, there was no functional improvement in coronary collateral resistance, because myocardial perfusion at rest and vasodilation did not change. Figure 8 . icMSCs increase LAD myocyte nuclear number and regress cellular hypertrophy in hibernating myocardium.
To determine whether the increased number of myocytes in the cell cycle led to pathological evidence of repair, we quantified myocyte nuclear density and derived myocyte number using nuclear length. icMSCs did not alter myocyte nuclear density (a), myocyte size (b), or number (c) in sham-normal animals (left graph). In untreated hibernating myocardium, LAD myocyte nuclear density was reduced, with an increase in myocyte diameter and reduction in myocyte number. After icMSC administration, there was a progressive increase in LAD myocyte nuclear density and number (right graph). This was accompanied by a reduction in myocyte diameter and a large increase in the calculated number of myocytes, which approached normal after 6 weeks. These data indicate substantial myocyte regeneration in an experimental model that is devoid of ongoing cell death.
icMSC administration, which suggests that the capillary density-myocyte density ratio was maintained as myocytes proliferated. Nevertheless, because capillaries contribute little resistance to perfusion, there was no significant increase in coronary flow during vasodilation, which indicates that there was no proliferation of functional coronary resistance vessels supplying the collateral-dependent region. The lack of effect on functional collateral flow is similar to findings after pharmacological mobilization of BMPCs by use of pravastatin in a similar model. 23 This supports a primary myocyte mechanism for the improvement in regional wall thickening and indicates that capillary density changes are not a reliable surrogate measure of myocardial perfusion. Multiple mechanisms are likely operative in producing improvements in function independent of myocardial perfusion. We have demonstrated that sarcoplasmic reticulum calcium handling proteins 39 and a broad array of mitochondrial proteins 40 are downregulated in chronic hibernating myocardium. Regression of cellular hypertrophy attendant with MSC-mediated myocyte proliferation would presumably restore many of the contractile and metabolic pathways altered in the hypertrophied myocytes. Other investigators have demonstrated that hypertrophied myocytes have reductions in contractile function in remodeled myocardium that reflect myofilament alterations and are independent of perfusion. 41 It is also possible that MSCs or their paracrine mediators provide protection of the hibernating region against repetitive ischemia-induced stunning, that may contribute to a component of dysfunction in hibernating myocardium. 42, 43 Further studies will be required to evaluate these potential mechanisms in detail.
Sources of New Cardiomyocytes and Myocyte Turnover
Cardiomyocytes are capable of self-renewal through proliferation from an endogenous cKit ϩ progenitor cell population. 44 Convincing experimental evidence suggests that self-renewal is an ongoing process, with myocyte turnover increasing with aging and with structural heart disease. 45 Self-renewal is critical to maintain myocyte number in the face of continuous loss from even low rates of apoptosis. 46 Other studies support the notion that BMPCs can populate the heart and adopt a cardiomyogenic phenotype as a source of myocyte renewal. 47 The present results indicate that icMSCs are capable of increasing the cKit ϩ / CD133 ϩ progenitor cell pool and, in contrast to MSCs administered via intramyocardial injection, do so throughout the entire heart. The downstream development of myocytes, however, appears to be regulated by endogenous substrate factors that are unique to the diseased heart, because MSC-mediated increases in cKit ϩ and CD133 ϩ cells do not promote mitosis (phosphohistone H3) or proliferation of normal cardiomyocytes. Because myocyte apoptosis was similar to that in normal hearts at the time we began our studies, increases in myocyte nuclear density after icMSC administration reflected cell regeneration. In contrast, MSC-mediated inhibition of cell death plays an important role in preserving myocytes in infarct or heart failure models. 25 A key question is whether the significant increase in myocyte nuclear density that occurs after icMSC administration in hibernating hearts is the result of resident cKit ϩ cardiac stem cells differentiating into adult myocytes, 4 differentiation of cKit ϩ / CD133 ϩ BMPCs into cardiac myocytes, 48 or stimulation of adult cardiomyocytes to reenter the cell cycle and divide. 49 The present data support any or all of these mechanisms. For example, after 2 weeks, we demonstrated that subpopulations of cKit ϩ cells and CD133 ϩ cells coexpressed GATA4, Nkx2.5, or troponin I, which supports their potential to differentiate into cardiomyocytes. After 6 weeks, however, CD133 ϩ cells returned to baseline levels, and only cKit ϩ cells remained elevated. This could reflect the fact that the CD133 ϩ cells have replenished the cardiac niche, as suggested by others using labeled bone marrow transplantation experiments in rodents, 50 or it could indicate persistent stimulation of the cardiac stem cell pool to proliferate. Regardless of origin, the number of cKit ϩ cells coexpressing cardiomyocyte markers (17 cells/cm 2 ) was lower than troponin I-positive, phospho-histone H3-positive myocytes (24 cells/cm 2 ) or Ki67 ϩ cardiomyocytes (350 cells/ cm 2 ). All of these were much lower than the cumulative increase in myocyte nuclear density (18 600 myocytes/cm 2 at 6 weeks, an average increase of 440 myocyte nuclei/cm 2 per day). Definitively quantifying the contribution of each of these potential sources to newly regenerated myocytes is not currently possible in the porcine model.
MSCs Increase cKit ؉ /CD133 ؉ and cKit ؉ /CD133 ؊ Cells in the Myocardium
Collectively, the present results identify a novel mechanism whereby icMSCs transiently increase myocardial cKit ϩ / CD133 ϩ BMPCs, which is followed by a persistent increase in cKit ϩ /CD133 Ϫ resident stem cells. Because CD133 ϩ cells are not present in the normal heart, the former supports the possibility of a bone marrow origin of the progenitor cells involved in cardiac repair. 47, 51 On the other hand, the presence of cKit ϩ / CD133 Ϫ cells is consonant with a recent study demonstrating that intramyocardial injection of MSCs stimulated the proliferation of cKit ϩ cells in infarct border zones. 38 In contrast to a localized effect at the border between normal and infarcted tissue, the intracoronary administration of MSCs produced myocyte proliferation throughout the heart and reduced cellular hypertrophy. Whether a similar benefit would occur when myocardial infarction is present is unclear, but the potential of icMSCs to stimulate myocyte proliferation and ameliorate dysfunction in remote remodeled myocardium after infarction could be as important as scar replacement.
Myocardial CD133 ϩ and cKit ϩ cells increased similarly after icMSC administration in normal and hibernating hearts, as well as after the infusion of MSCs into the descending aorta. The latter finding indicates that myocardial injection or microembolization is not required and suggests a systemic action that may arise from a paracrine mediator or homing of the MSCs back to the bone marrow. Multiple paracrine factors have been implicated in explaining the beneficial actions of MSCs. 25 In our previous studies in the Syrian hamster with heart failure, we demonstrated the potential role of paracrine factors in mobilizing BMPCs after repetitive skeletal muscle injection of porcine MSCs, MSC media, and vascular endothelial growth factor. 24, 26, 52, 53 The effects of single injections of MSC media in swine are controversial. 38, 54 Some of the paracrine candidates secreted by porcine MSCs include vascular endothelial growth factor, insulin-like growth factor-1, and interleukin-6, and we have recently demonstrated that these converge to activate the JAK/STAT pathway. 53 The differential upregulation of stromal cell-derived factor-1 and monocyte chemotactic protein-1 in hibernating myocardium after icMSC administration are but 2 of what are likely many potential candidates involved in the model of hibernating myocardium.
Given the ability of CD133 ϩ BMPCs to coexpress cardiac lineage markers, including GATA-4, Nkx2.5, and troponin I, we propose that some of the myocyte proliferation that results from icMSCs reflects the transdifferentiation of endogenous BMPCs mobilized to the heart. Although transdifferentiation of MSCs into myocytes is not seen after icMSC administration, the present data also support the possibility that, like intramyocardial MSC injections, 38 icMSCs promote myocyte proliferation by activation of a resident cKit ϩ /CD133 Ϫ cardiac stem cell pool. The similarity of these changes to the functional improvement and mobilization of CD133 ϩ and cKit ϩ myocardial cells after chronic administration of pravastatin in pigs with hibernating myocardium is striking. 23 The present findings after icMSC administration are also consonant with recent reports that suggest that paracrine-mediated stimulation of endogenous cardiac myocyte proliferation is responsible for many of the beneficial effects seen after intracoronary administration of cardiac stem cells, as well as intramyocardial cardiosphere-derived cells, in infarct models. 38, 55, 56 Further studies will be required to determine whether the actions of MSCs are additive to similar effects demonstrated pharmacologically with pravastatin, but a synergistic effect could result in more prominent myocyte regeneration of failing, noninfarcted myocardium.
Methodological Limitations
We did not measure circulating cKit ϩ and CD133 ϩ cells 6 weeks after icMSC administration, but circulating cKit ϩ cells were probably low, because they were already near baseline at 2 weeks. Likewise, because tissue CD133 ϩ cell levels returned to baseline at 6 weeks, it would seem unlikely that circulating levels would be increased. Although the present results quantify the cumulative extent of myocyte regeneration and its translational relevance in a large animal model of chronic ischemia, mechanistic insight regarding the contribution of each progenitor cell subtype will require technically challenging studies in which genetic fate mapping, bone marrow transplantation, and reporter gene imaging can be applied using rodent models of chronic ischemia.
Clinical Implications
The present study provides a rationale for the clinical evaluation of the effects of intracoronary administration of MSCs in humans with viable dysfunctional myocardium with residual perfusion. The clinical relevance of this substrate as a therapeutic target is high, 57 and recent clinical trials have demonstrated no effect of revascularization on survival in ischemic heart failure. 58 Viable dysfunctional myocardium is common and arises secondary to hibernating myocardium and repetitive stunning, as well as from myocyte loss and cellular hypertrophy due to LV remodeling. 59, 60 In contrast to avascular fibrotic scar, there is residual perfusion, which permits the distribution of intracoronary cell-based therapy by standard cardiac catheterization approaches. Importantly, although much preclinical investigation has focused on heart failure due to postinfarction remodeling after massive transmural infarcts in rodent models, contemporary reperfusion strategies in patients limit postinfarction heart failure and remodeling. For example, in a recent large clinical trial, average ejection fraction in unselected patients after first ST-elevation infarction was near normal (Ϸ50%). 61 Scar volume initially averaged only Ϸ15% of the LV and decreased further over the ensuing months because the acute infarct normally contracts. When heart failure develops in ischemic cardiomyopathy, there is diffuse rather than single-vessel coronary artery disease and patchy fibrosis. Even in explanted hearts of patients with end-stage heart failure, fibrosis only averages 28% of the LV, and nearly three quarters of the heart is viable yet dysfunctional. 62 Thus, the fundamental problem in many patients with contractile dysfunction may be myocyte loss from progressive apoptosis induced by elevated preload, neurohormonal activation, reversible ischemia, and other factors, rather than the development of a massive infarct. 62 Such a circumstance can develop with multiple regions of hibernating myocardium in the absence of any infarction. 63 On the basis of our findings, a paradigm of initiating cardiac repair to prevent heart failure by reversing myocyte loss, cellular remodeling, and regional dysfunction before progression to severely decompensated LV dysfunction and failure may prove to be more successful than implementing therapy to treat end-stage disease.
Novelty and Significance
What Is Known?
• Intramyocardial injection of mesenchymal stem cells (MSCs) improves myocardial function in animal models of infarction. • MSCs variably effect myocyte proliferation, inhibit myocyte death, and reduce scar volume, but the relative importance of each of these mechanisms to repair is unknown. • Although controversial, transdifferentiation of MSCs into cardiomyocytes and stimulation of resident cardiac stem cells has been demonstrated in infarct border zones, but the importance of these localized changes to improved global function is unknown.
What New Information Does This Article Contribute?
• Intracoronary MSCs improve regional function independent of flow in swine with hibernating myocardium. • Functional improvement arises from de novo myocyte proliferation, and the resultant increase in cardiomyocytes leads to regression of cellular hypertrophy throughout the dysfunctional region. • Although intracoronary MSCs do not transdifferentiate into cardiomyocytes, they increase myocardial bone marrow progenitor cells and resident cardiac stem cells; both subtypes can transdifferentiate into cardiomyocytes.
Many stem cell therapies are effective at improving function and increasing capillary density after infarction in animal models. Nevertheless, viable dysfunctional states due to hibernating myocardium, stunning, and LV remodeling rather than scar underlie the contractile dysfunction seen in many patients with ischemic cardiomyopathy. Our studies, in a model devoid of scar and ongoing apoptosis, demonstrate the quantitative impact of MSC-mediated cardiomyocyte proliferation when residual perfusion is present. We show that readily implemented infusion of MSCs to all of the major coronary arteries improves contractile function as a result of a marked increase in myocyte numbers and secondary regression of cellular hypertrophy in hibernating myocardium. There is no evidence that the myocytes arise from transdifferentiation of MSCs when administered by this route. Rather, de novo myocyte regeneration arises from transdifferentiation of myocardial bone marrow (CD133 ϩ ) and resident (cKit ϩ ) progenitor cells that are increased after MSCs in a fashion similar to that demonstrated pharmacologically with pravastatin. Although the relative contributions of each source of new myocytes remains to be defined, the results suggests that intracoronary MSC administration to patients with viable dysfunctional myocardium with residual perfusion may afford a more favorable substrate for repair than fibrotic scar.
